Navigation Links
Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed Inc. (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored study of the company's drug, IPLEX(TM), in patients with myotonic muscular dystrophy (DM1).

Preliminary results of the clinical study, being conducted at the University of Rochester School of Medicine and Dentistry, showed that six months of treatment with doses of IPLEX up to 1 mg/kg/day in six patients met the primary study endpoints of being safe and well tolerated. In addition, IPLEX treatment was associated with improvements in muscle mass, cholesterol and triglycerides. During the six months of treatment, 5 out of 6 patients experienced an improvement in lean muscle mass. Patients also reported improvement in gastrointestinal function, endurance and cognitive function during treatment with IPLEX.

"We are very encouraged by the results from this preliminary study of IPLEX in myotonic dystrophy. The results not only indicate IPLEX was safe, well tolerated and had a positive effect on muscle and lipid metabolism, they also suggest IPLEX may have a positive effect on aspects of the disease that affect patients' daily living," said Dr. Geoffrey Allan, president and CEO of Insmed.

Study Description

The primary objectives of this ongoing open-label, Phase II dose escalation study are to examine the safety and tolerability of once-daily, subcutaneous injection of IPLEX in up to 15 patients with DM1 and to identify the maximum tolerated dose. The next cohort of patients will be treated for six months with a dose of IPLEX which will be titrated up to 2 mg/kg/day.

The study is funded by the National Institutes of Health and the Muscular Dystrophy Association, with supply of IPLEX drug provided by Insmed. A Phase II, placebo-controlled study to further investigate the safety and efficacy of IPLEX in a larger number of patients with DM1 is being des
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
2. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:6/2/2015)... et MADRID , June ... orale (extrait 10503) effectuée lors de la réunion ... PharmaMar communique que Janssen Research & ... de l,étude multicentrique de phase III SAR3007 qui ... progression (PFS) avec la trabectédine (YONDELIS ® ) ...
(Date:6/1/2015)... , June 2, 2015 Amgen ... with Roche on a Phase 1b study to ... Amgen,s investigational oncolytic immunotherapy, in combination with Roche,s ... in patients with triple-negative breast cancer and colorectal ... is an investigational oncolytic immunotherapy designed to selectively ...
(Date:6/1/2015)... June 1, 2015 Lee Tran ... the Snapchat and Yik Yak ... against one of the most promising biotechnology start-ups in ... Meyer and Jeffrey Sabados .  LTL represents ... a former colleague and fellow scientist at the Massachusetts ...
Breaking Medicine Technology:PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2
... , ... ... ... ...
... ... ... ... , ...
Cached Medicine Technology:Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 2Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 3Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 4Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 5Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 6Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 7Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 8Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 9Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 10Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 11Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 12Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 13Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 14Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 15Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 16Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 17Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 18Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 2Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 3Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 4Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 5
(Date:6/2/2015)... June 02, 2015 Atlantic Spine ... spine surgery with three locations in New Jersey, announces ... City. The new facility is at 1045 Park Avenue ... consultations and appointments can be arranged by calling 1-844-912-2406. ... at Atlantic Spine Center, has been a pioneer in ...
(Date:6/2/2015)... SB 277 (CA Legislature, bit.ly/1Q0P8OY) will require ... public or private school. SB277 cleared three Senate policy ... Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). It passed ... “We believe that this bill affects the education of ... will (the) affect public health of California.. It is ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Miriam Wirski as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to present Miriam with this prestigious honor,” said NAPW ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Marcy Herrmann as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... honor to present Marcy with this distinction,” said NAPW ...
Breaking Medicine News(10 mins):Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... twins were conjoined from the breast bone to the ... pediatricians and nurses at Children,s Hospital of Pittsburgh of ... procedure.The 2-year-old twin girls -- Dagian and Danielle Lee, ... began at 6:30 a.m. Saturday, Dec. 13, 2008, and ...
... lead to more headaches, new study suggests , , MONDAY, Feb. ... by taking naps to sleep it off, but they run ... patterns and perpetuating the cycle of headaches, a new study ... things people tried to treat their headaches, and they rated ...
... a statement by American Heart Association President Timothy Gardner, ... provisions in the economic stimulus package are a win-win ... with increased financial burdens. Americans suffering from chronic ... -- see a doctor or pay for food and ...
... One of the nation,s first group of fertility ... cost reduction to patients challenged by economic downturnSAN ... a 25th-anniversary celebration, one of the nation,s first ... to couples and individuals struggling to find ways ...
... ARLINGTON, Texas, Feb. 16 Across the nation, countless ... executives at one North Texas healthcare company took some ... from being another victim to the economic crisis.2009 looks ... now in its 7th year. One year ago ten ...
... AlphaVax announced today that it has ... Regulatory, Quality and Clinical Operations. In this capacity ... the areas of regulatory and quality affairs and ... trials, developing regulatory strategy and gaining regulatory approval ...
Cached Medicine News:Health News:Conjoined Twins Separated by Surgical Team at Children's Hospital of Pittsburgh of UPMC During Complex, 24-Hour Procedure 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:Statement by American Heart Association President Timothy Gardner, M.D. on Congressional Approval of Economic Stimulus Package 2Health News:Bay Area Fertility Clinic to Offer Special Help During Recession 2Health News:Staying Healthy in 2009 2Health News:AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations 2
Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....
TBR-120-1-GD is large capacity upright style refrigerator with an operating temperature of +4C. It is a specially designed refrigerator for the storage of blood in standard 500ml bags, complying with...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
... is a direct competitive EIA for ... human serum or plasma. A specific ... making it available for antibody binding. ... antibody linked to fluorescein isothiocyanate (FITC) ...
Medicine Products: